Free tool
FAERS Monitor: Micafungin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212156 or its brand name (Micafungin, Micafungin Sodium). Reports on generic versions are filed under their own applications.
Reports
6,576
Serious
6,281
96% of reports
Hospitalization
3,207
Death reported
2,438
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,105
- off label use691
- pyrexia487
- febrile neutropenia435
- product use in unapproved indication320
- pneumonia313
- sepsis308
- multiple organ dysfunction syndrome281
- diarrhoea271
- neutropenia264
- acute kidney injury254
- respiratory failure244
- septic shock229
- condition aggravated202
- bronchopulmonary aspergillosis182
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 11 |
| 2005 | 18 |
| 2006 | 30 |
| 2007 | 55 |
| 2008 | 49 |
| 2009 | 48 |
| 2010 | 85 |
| 2011 | 172 |
| 2012 | 200 |
| 2013 | 143 |
| 2014 | 175 |
| 2015 | 315 |
| 2016 | 259 |
| 2017 | 353 |
| 2018 | 460 |
| 2019 | 481 |
| 2020 | 459 |
| 2021 | 539 |
| 2022 | 529 |
| 2023 | 568 |
| 2024 | 577 |
| 2025 | 605 |
| 2026 | 445 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,583 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| bronchopulmonary aspergillosisSignal | 182 | 76.8 | 66.5 | 13,236 |
| multiple organ dysfunction syndromeSignal | 281 | 32.0 | 28.6 | 8,346 |
| febrile neutropeniaSignal | 435 | 21.1 | 19.3 | 8,283 |
| septic shockSignal | 229 | 16.9 | 14.9 | 3,403 |
| respiratory failureSignal | 244 | 10.7 | 9.5 | 2,144 |
| sepsisSignal | 308 | 8.9 | 7.9 | 2,143 |
| neutropeniaSignal | 264 | 6.2 | 5.5 | 1,157 |
| acute kidney injurySignal | 254 | 5.3 | 4.7 | 891 |
| pyrexiaSignal | 487 | 4.5 | 4.1 | 1,346 |
| product use in unapproved indicationSignal | 320 | 4.1 | 3.7 | 765 |
| pneumoniaSignal | 313 | 3.1 | 2.8 | 448 |
| drug ineffectiveSignal | 1,105 | 2.7 | 2.5 | 1,242 |
| off label useSignal | 691 | 2.5 | 2.4 | 662 |
| condition aggravatedSignal | 202 | 2.1 | 1.9 | 121 |
| diarrhoea | 271 | 1.3 | 1.2 | 24 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.